NEA Management Company, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), NEA Management Company, LLC reported 26 stock positions worth $1.8 billion. Its top holding was Arcellx (ACLX) at 19.9% of the portfolio, followed by Celcuity (CELC, 14.8%) and Spyglass Pharma (SGP, 10.9%). Compared with Q4 2025, it opened 1 new position, sold out of 2, added to 2 and reduced 2. The biggest buy was a new position in Spyglass Pharma (SGP) and the biggest sale an exit from Rhythm Pharmaceuticals (RYTM).

Most Recent 13F
Q2 2026
Location
TIMONIUM, MD
CIK
0001512848
Portfolio Value
$1.8B (Q1 2026)
SEC Filing
0001072613-26-000458 ↗ filed May 15, 2026

Holdings Value

0$500.0M$1.0B$1.5B$2.0B Q1 2024: $1.6B Q1 2024 Q2 2024: $1.3B Q2 2024 Q3 2024: $1.8B Q3 2024 Q4 2024: $1.8B Q4 2024 Q1 2025: $1.3B Q1 2025 Q2 2025: $1.3B Q2 2025 Q3 2025: $1.8B Q3 2025 Q4 2025: $2.0B Q4 2025 Q1 2026: $1.8B $1.8B Q1 2026 Q2 2026: $1.6B Q2 2026

Holdings 26 stocks · $1.8B
ACLX Arcellx Inc. 19.88% 3,045,262 $349.7M No change
CELC Celcuity Inc. 14.83% 2,285,561 $260.9M Reduce -35.4%
SGP Spyglass Pharma Inc. 10.89% 7,392,301 $191.5M New
TRVI Trevi Therapeutics Inc. 8.97% 13,222,228 $157.7M No change
SVRA Savara Inc. 7.60% 24,471,264 $133.6M No change
GLUE Monte Rosa Therapeutics Inc. 7.19% 7,692,298 $126.5M No change
MBX MBX Biosciences Inc. 6.13% 3,614,486 $107.9M No change
ZBIO Zenas Biopharma Inc. 4.47% 4,023,219 $78.7M Add +14.2%
COUR Coursera Inc. 4.26% 12,867,769 $74.9M No change
AUPH Aurinia Pharmaceuticals Inc. 3.34% 3,969,834 $58.8M No change
ORIC Oric Pharmaceuticals Inc. 2.97% 4,118,621 $52.2M No change
CRSP Crispr Therapeutics AG 2.86% 1,058,570 $50.4M No change
PHAT Phathom Pharmaceuticals Inc. 1.24% 1,960,169 $21.8M No change
CVRX CVRX Inc. 1.09% 2,026,083 $19.2M No change
KRRO Korro Bio Inc. 0.84% 1,297,893 $14.7M Add +19.0%
XFOR X4 Pharmaceuticals Inc. 0.76% 3,233,743 $13.4M No change
CSBR Champions Oncology Inc. 0.56% 1,713,720 $9.9M No change
BDTX Black Diamond Therapeutics I 0.54% 4,448,757 $9.5M No change
IVA Inventiva SA - ADR 0.46% 1,462,586 $8.0M No change
NKTX Nkarta Inc. 0.43% 3,568,781 $7.5M No change
LONA Leonabio Inc. 0.27% 464,398 $4.8M No change
SNTI Senti Biosciences Inc. 0.17% 3,775,615 $3.1M No change
MRKR Marker Therapeutics Inc. 0.12% 1,625,678 $2.1M No change
OKUR Onkure Therapeutics Inc. Class A 0.11% 478,548 $2.0M No change
GOSS Gossamer Bio Inc. 0.02% 1,000,000 $329K Reduce -94.5%
IMA Imagenebio Inc. 0.01% 50,005 $250K No change

Portfolio Sells Q4 2025 → Q1 2026
RYTM Rhythm Pharmaceuticals Inc. Sold out 0.00% −15.88
CELC Celcuity Inc. Reduce -35.4% 14.83% −3.15
GOSS Gossamer Bio Inc. Reduce -94.5% 0.02% −2.84
SYBX Synlogic Inc. Sold out 0.00% −0.17

Portfolio Buys Q4 2025 → Q1 2026
SGP Spyglass Pharma Inc. New 10.89% +10.89
KRRO Korro Bio Inc. Add +19.0% 0.84% +0.39
ZBIO Zenas Biopharma Inc. Add +14.2% 4.47% −2.05

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 26$1.6BTRVI, MBX, GLUE, CELC, SGP
Q1 2026 26$1.8BACLX, CELC, SGP, TRVI, SVRA
Q4 2025 27$2.0BCELC, RYTM, ACLX, TRVI, SVRA
Q3 2025 29$1.8BRYTM, ACLX, VRNA, COUR, TRVI
Q2 2025 32$1.3BACLX, VRNA, RYTM, COUR, CRSP
Q1 2025 37$1.3BACLX, VRNA, RYTM, TEM, COUR
Q4 2024 41$1.8BACLX, VRNA, TEM, RYTM, NN
Q3 2024 42$1.8BACLX, TEM, VRNA, RYTM, SVRA
Q2 2024 41$1.3BACLX, TEM, RYTM, SVRA, COUR
Q1 2024 44$1.6BACLX, CRSP, RYTM, SVRA, COUR